Osteosarcoma in Dogs: A Complete Guide for Dog Owners

Understanding Bone Cancer: Diagnosis, Pain Management, Treatment, and Prognosis

A diagnosis of osteosarcoma is one of the most devastating words a dog owner can hear. It is a cancer that moves fast, causes profound pain, and demands difficult decisions — often within days of diagnosis. And yet, understanding this disease in depth gives families something critically important: the ability to make informed, compassionate choices for their dogs.

Osteosarcoma (OSA) is the most common primary bone tumor in dogs, accounting for approximately 85 percent of all skeletal malignancies in the species. It is an aggressive cancer with a high rate of early metastasis, and it disproportionately affects large and giant breeds. But osteosarcoma is also a disease where treatment advances have meaningfully extended survival and quality of life — and where an emerging understanding of its biology is opening new therapeutic frontiers.

This guide covers everything you need to know: what osteosarcoma is, which dogs it targets, how it presents and is diagnosed, what treatment options exist, how to manage pain, what to realistically expect, and the most common questions families face when navigating this difficult diagnosis.

What Is Osteosarcoma?

Osteosarcoma is a malignant tumor arising from osteoblasts — the cells responsible for forming bone. In their cancerous form, these cells produce abnormal osteoid (immature bone matrix) while simultaneously destroying normal bone architecture. The result is a progressive, painful lesion that weakens the affected bone from within, eventually predisposing it to pathologic fracture.

The biological behavior of canine osteosarcoma is aggressive and well-characterized. At the time of clinical diagnosis, the vast majority of dogs — estimated at 90 to 95 percent — already have microscopic metastatic disease, most commonly to the lungs. This micrometastatic burden is typically undetectable on standard imaging at diagnosis (only about 10 percent of dogs have visible metastasis on imaging at presentation), but it is the primary reason that local treatment alone yields relatively short survival times. Treating OSA effectively means addressing both the primary tumor and the systemic disease simultaneously.

Canine osteosarcoma has drawn significant interest from human oncologists because of its remarkable biological similarity to pediatric osteosarcoma in children — one of the most striking examples of naturally occurring comparative oncology. Research advances in dogs have directly informed human treatment protocols, and vice versa.

Research Note: Canine osteosarcoma is biologically nearly identical to pediatric osteosarcoma in children. Dogs with OSA are considered one of the most valuable natural animal models in all of cancer research, and discoveries in one species directly benefit the other.

Which Dogs Are Most at Risk?

Osteosarcoma is predominantly a disease of large and giant breed dogs, with body size and weight being among the strongest risk factors. The physics of bearing heavy loads on a skeletal frame, combined with the rapid bone growth during development, is believed to contribute to the elevated risk in larger animals.

High-Risk Breeds

• Scottish Deerhound — highest breed-specific odds ratio of any breed (OR 118.4 above baseline); OSA incidence rate of approximately 15 percent; heritability estimated at 0.69
• Leonberger — second highest odds ratio (OR 55.8); significantly elevated risk relative to body size
• Great Dane — very high risk (OR 34.2); one of the most frequently affected giant breeds
• Rottweiler — unusually high risk relative to body size (OR 26.7); strong and well-characterized genetic predisposition
• Irish Wolfhound — exceptionally high prevalence; approximately 12 percent of 10-year-old dogs in Swedish population studies had been diagnosed; OSA is a leading cause of death in the breed
• Greyhound — high risk; OSA accounts for a substantial proportion of mortality in some breed cohorts
• Saint Bernard
• German Shepherd Dog
• Doberman Pinscher
• Golden Retriever
• Labrador Retriever
• Boxer

The typical patient is a large or giant breed dog with a median age at diagnosis of approximately 7 to 9 years, though OSA can occur at any age. A bimodal age distribution has been noted, with a small peak in young dogs (under 2 years) and a larger peak in middle-aged to older animals. Sex predisposition has been inconsistently reported across studies — some find a slight male predominance, others find no significant difference. Neutered dogs of both sexes may have elevated risk compared to intact animals, though this relationship is complex and ongoing research continues to examine it.

Body weight is an independent risk factor. Dogs weighing more than 40 kilograms (approximately 88 pounds) have substantially elevated OSA risk compared to smaller dogs — and dogs weighing at or above the mean for their breed are approximately 1.65 times more likely to develop OSA than those below the breed mean. Small and toy breeds can develop osteosarcoma, but it is rare and tends to behave less aggressively when it does occur.

Risk Factor Note: Prior bone injury, previous fractures, and implanted metallic orthopedic hardware have all been identified as potential risk factors for osteosarcoma development at the affected site — though the absolute risk remains low.

Where Does Osteosarcoma Develop?

Approximately 75 to 80 percent of canine osteosarcomas arise in the appendicular skeleton — the limbs. The remaining 20 to 25 percent arise in the axial skeleton (skull, spine, ribs, pelvis, and other flat bones). A small subset — approximately 1 percent — arises in extraskeletal soft tissues.

Appendicular Osteosarcoma

Within the limbs, OSA overwhelmingly favors the metaphyseal regions — the areas adjacent to the growth plates — of the long bones. The mnemonic commonly taught in veterinary schools captures the distribution well: OSA develops "far from the elbow, close to the knee." More specifically:

Location	Approximate Frequency	Notes
Distal radius (forelimb)	~50% of appendicular OSA	Single most common site overall
Proximal humerus (forelimb)	~15%	Shoulder region; associated with worse prognosis
Distal femur (hindlimb)	~10%	Above the stifle/knee
Proximal tibia (hindlimb)	~10%	Below the stifle/knee
Proximal femur (hindlimb)	~5%	Hip region
Distal tibia (hindlimb)	~5%	Above the hock
Other long bone sites	~5%	Including fibula, ulna

The proximal humerus deserves special note: meta-analyses have confirmed that dogs with primary tumors at the proximal humerus have significantly shorter survival times — approximately 132 days shorter median survival — compared to dogs with tumors at other appendicular sites. This location should be considered an independent negative prognostic factor.

Axial Osteosarcoma

Axial OSA involves the skull, mandible, spine, ribs, sternum, and pelvis. These tumors are generally more difficult to treat surgically due to anatomical constraints, and local recurrence rates are higher. The prognosis for axial OSA is variable by site: OSA of the skull and jaw may behave somewhat differently from appendicular disease — some studies suggest lower rates of distant metastasis for craniofacial sites, with local progression being the primary cause of death — while spinal and pelvic OSA tends to carry a poor prognosis driven by both local invasion and systemic spread.

Recognizing the Signs: Clinical Presentation

Osteosarcoma of the appendicular skeleton classically presents with a single, progressive constellation of signs that owners often initially attribute to orthopedic injury or arthritis. Understanding the typical presentation can help owners seek evaluation before the disease has progressed significantly.

Primary Signs

• Lameness — typically sudden in onset, progressive over weeks to months, and eventually severe and non-weight-bearing; may appear to improve temporarily with rest or anti-inflammatories
• Localized swelling — a firm, often warm swelling over the affected bone; may be subtle early on
• Pain on palpation — the affected region is tender to touch; dogs may flinch, pull away, or vocalize
• Muscle atrophy — wasting of the musculature around the affected limb due to disuse
• Reluctance to exercise or play — reduced activity, especially activities that load the affected limb

The pain of osteosarcoma is considered among the most severe in veterinary medicine. It arises from multiple mechanisms: prostaglandin-mediated bone inflammation, mechanical disruption of the periosteum (the pain-sensitive outer bone covering), microfractures within the tumor, and — in advanced cases — pathologic fracture of the weakened bone. Dogs are stoic animals and often mask pain until it is severe, meaning visible lameness frequently represents substantial underlying suffering.

Signs of Axial OSA

• Facial swelling, nasal discharge, or nosebleeds (skull or nasal involvement)
• Difficulty eating or jaw pain (mandibular involvement)
• Neurological signs, paresis, or paralysis (spinal involvement)
• Respiratory signs, chest wall asymmetry (rib or sternal involvement)
• Hindlimb weakness or difficulty rising (pelvic or sacral involvement)

Warning: Do not assume limb swelling and lameness in a large breed dog is simply a sprain or arthritis. Osteosarcoma frequently presents this way and is misdiagnosed or delayed for weeks or months. Any progressive, non-improving lameness with localized swelling warrants radiographs.

Diagnosis

Diagnosis of osteosarcoma involves a combination of imaging, bloodwork, and tissue analysis. The goal is not only to confirm the diagnosis but to characterize the extent of local disease and determine whether distant metastasis is present — both of which are essential for treatment planning.

Radiography

Plain radiographs of the affected limb are typically the first and most informative diagnostic step. OSA produces characteristic radiographic changes that an experienced veterinary radiologist can often recognize with high confidence. Classic findings include a "sunburst" pattern of periosteal new bone formation, a "Codman's triangle" at the periosteal margins, mixed lytic and productive bone changes in the metaphyseal region, and soft tissue swelling surrounding the lesion. These findings, in the right location and in a large breed dog, are strongly suggestive of OSA — many clinicians proceed directly to treatment planning based on radiographic findings alone when the presentation is typical.

Fine Needle Aspirate Cytology

Fine needle aspirate (FNA) cytology is a minimally invasive, cost-effective, and widely used first-line diagnostic tool for suspected OSA. Studies have demonstrated an overall diagnostic accuracy of 83 to 92 percent for correctly identifying malignancy from bone lesions.

When a diagnosis of sarcoma is made on cytology, alkaline phosphatase (ALP) staining can be applied to confirm osteosarcoma specifically, with a reported sensitivity of 100 percent. Many veterinary oncologists now rely on FNA cytology as their primary pre-operative diagnostic approach, particularly when the clinical and radiographic presentation is typical.

FNA can often be performed with sedation rather than general anesthesia, making it faster and lower risk than surgical biopsy.

Bone Biopsy

Histopathological confirmation via bone biopsy remains the definitive gold standard and is preferred in cases where radiographic and cytologic findings are atypical, when differentiation from other primary bone tumors (such as chondrosarcoma or fibrosarcoma) is clinically important, or when the diagnosis may significantly alter the treatment approach. Biopsy is performed via Jamshidi needle (core biopsy) or open surgical biopsy under general anesthesia. It carries a small risk of pathologic fracture at the biopsy site and should be planned carefully.

Current guidelines note that it is acceptable to establish a final diagnosis histopathologically after amputation when signalment, clinical signs, and radiographic findings are all consistent with OSA.

Staging Workup

• Thoracic radiographs (3 views) or thoracic CT — pulmonary metastasis screening; CT detects smaller nodules
• Abdominal ultrasound — abdominal organ involvement and lymph node assessment
• Regional lymph node aspirate — if nodes are enlarged
• Bone scan (nuclear scintigraphy) — sensitive detection of skeletal metastasis or polyostotic disease (multiple bone involvement)
• Complete blood count and serum chemistry — baseline assessment; alkaline phosphatase elevation is a notable prognostic marker
• Serum alkaline phosphatase (ALP) — elevated ALP, particularly bone-specific ALP, is associated with worse prognosis

Prognostic Marker: Elevated serum alkaline phosphatase at diagnosis is one of the most consistently identified negative prognostic factors in canine OSA. Dogs with elevated ALP have significantly shorter survival times than those with normal levels, independent of other factors.

Treatment Options

Osteosarcoma management requires a multimodal approach addressing both the primary tumor and the systemic disease. Treatment decisions are shaped by tumor location, disease stage, patient health status, and owner goals for quality and quantity of life.

Amputation

Surgical amputation of the affected limb remains the gold standard for local tumor control in appendicular OSA. It provides immediate, complete relief from the severe bone pain associated with the primary tumor and removes the risk of pathologic fracture. Dogs adapt to three-legged life (tripod life) with remarkable resilience; most large breed dogs are bearing weight and moving comfortably within days to weeks of amputation. Quality of life studies consistently demonstrate that dogs who have undergone amputation maintain excellent mobility and apparent wellbeing.

Amputation alone, without chemotherapy, yields a median survival of approximately 4 months. This relatively short survival reflects the high burden of microscopic metastatic disease present at diagnosis. Amputation is therefore considered incomplete treatment for OSA when used without adjuvant chemotherapy.

Limb-Sparing Surgery

For owners who cannot accept amputation — due to concurrent orthopedic disease in other limbs, body condition concerns, or personal preferences — limb-sparing surgery is available at specialized veterinary surgical centers. The procedure involves resection of the tumor-bearing bone segment and reconstruction with a bone allograft, endoprosthesis, or a combination.

Limb-sparing is most feasible and best studied for distal radial OSA.

Complication rates are substantial, including infection, implant failure, and local tumor recurrence, and require a committed owner and access to specialized postoperative care. Survival times with limb-sparing plus chemotherapy are comparable to amputation plus chemotherapy in appropriately selected patients.

Stereotactic Body Radiation Therapy (SBRT)

Stereotactic body radiation therapy (SBRT) — sometimes called stereotactic radiosurgery — delivers precisely targeted, high-dose radiation to the tumor in a small number of fractions (typically 1 to 5 treatments).

It is now considered a routine option for local tumor control at institutions with the necessary equipment, and the 2024 Updates in Osteosarcoma review identifies limb-sparing approaches including SBRT as standard of practice at specialized centers. SBRT offers good to excellent pain palliation and, when combined with chemotherapy, survival outcomes comparable to surgical approaches in selected patients. A 2021 retrospective study of 123 dogs treated with SBRT reported median survival times consistent with surgery-based approaches.

Palliative Radiation Therapy

Conventional fractionated palliative radiation therapy (typically 4 weekly doses) provides effective pain relief in approximately 70 to 80 percent of dogs with OSA.

Pain relief typically begins within 1 to 2 weeks of initiating treatment and can last several months.

Palliative radiation does not have meaningful anti-tumor effects at the doses used, but it addresses the primary quality-of-life concern — severe bone pain — without requiring surgery. It is an important option for dogs who are not surgical candidates or whose owners prefer a non-amputative approach.

Chemotherapy

Adjuvant chemotherapy following amputation is the current standard of care for canine OSA and is responsible for approximately doubling median survival compared to surgery alone. Chemotherapy targets the micrometastatic disease present at diagnosis that ultimately causes death in the vast majority of patients. Protocols in common use include:

• Carboplatin — a platinum-based agent; the most commonly used single agent for canine OSA; typically administered every 3 weeks for 4 to 6 cycles; median survival of approximately 10 to 11 months
• Doxorubicin — an anthracycline agent with established efficacy; used as a single agent or alternating with carboplatin; median survival approximately 10 months
• Carboplatin + doxorubicin alternating protocol — a widely used combination; typically 6 cycles over 18 weeks; median survival approximately 10 to 13 months
• Cisplatin — an older platinum agent; less commonly used now due to nephrotoxicity and the availability of carboplatin

With amputation plus adjuvant chemotherapy, approximately 50 percent of dogs are alive at 1 year after diagnosis, and roughly 20 to 25 percent survive beyond 2 years. A small but meaningful subset achieves long-term remission.

Pain Management

Regardless of the treatment path chosen, aggressive multimodal pain management is an ethical imperative in OSA care. The pain of osteosarcoma is severe, and undertreating it significantly diminishes quality of life. Pain management protocols typically include multiple agents targeting different pain pathways:

• NSAIDs (carprofen, meloxicam, or deracoxib) — foundational analgesic; reduce prostaglandin-mediated bone pain
• Gabapentin — neuropathic pain component; often used in combination with NSAIDs
• Tramadol — a weak opioid with modest evidence in dogs; used as part of multimodal protocols
• Amantadine — NMDA receptor antagonist; added for central sensitization and breakthrough pain
• Bisphosphonates (pamidronate, zoledronate) — IV infusions that inhibit osteoclast activity, reduce bone resorption, and have direct analgesic effects; given monthly alongside other treatments
• Oral opioids — buprenorphine or other opioids for breakthrough pain as disease progresses
• Palliative radiation — for temporary relief of primary tumor pain

Pain Management Pearl: Bisphosphonate therapy (pamidronate or zoledronate infusions) is one of the most underutilized yet effective palliative tools for OSA pain management. Monthly IV infusions significantly reduce bone pain, slow pathologic fracture risk, and may provide modest anti-tumor effects.

Prognosis: Understanding Survival Data

Treatment Approach	Median Survival	Notes
No treatment (palliative only)	1–4 months	Pain management focus
Palliative radiation alone	4–6 months	Pain relief; no systemic control
Amputation alone	~4 months	Local control; micrometastasis progresses
Amputation + carboplatin	10–11 months	~50% alive at 1 year
Amputation + doxorubicin	~10 months	Comparable to carboplatin
Amputation + alternating protocol	10–13 months	Most commonly used combination
Limb-sparing + chemotherapy	10–13 months	Comparable to amputation in select cases
SBRT + chemotherapy	~10–14 months	Emerging; comparable to surgery in early data

These survival statistics represent population medians — meaning half of all treated dogs will do better, and half will do worse. Prognostic factors that influence individual outcomes include serum alkaline phosphatase levels, lymph node involvement, tumor location, presence of detectable metastasis at diagnosis, and histological subtype.

Negative Prognostic Factors

• Elevated serum alkaline phosphatase — the single most consistently validated negative prognostic factor across multiple studies and meta-analyses
• Elevated bone-specific alkaline phosphatase
• Proximal humerus as primary tumor site — associated with approximately 132 days shorter median survival vs. other appendicular sites
• Regional lymph node involvement
• Detectable pulmonary metastasis at diagnosis
• High tumor proliferation index on histopathology
• Pathologic fracture prior to or at diagnosis

It is important to acknowledge that the prognosis for canine OSA, even with optimal treatment, remains guarded. The majority of dogs treated with amputation and chemotherapy will succumb to metastatic disease within 12 to 18 months. However, quality of life during that period — with adequate pain management and appropriate supportive care — can be genuinely good, and the meaningful subset of long-term survivors gives families reason for cautious hope.

Emerging and Investigational Treatments

Osteosarcoma research in dogs is active and accelerating, driven in part by the species' role as a comparative oncology model. Several promising approaches are under investigation.

Immunotherapy

Immune-based approaches represent the most exciting frontier in OSA treatment. The ADXS-HER2 (also known as OST-HER2) platform — a Listeria-based vaccine targeting the HER2/neu receptor, which is overexpressed in approximately 40 percent of canine OSA tumors — showed striking results in a pilot study: disease-free interval of 615 days, median survival of 956 days, and 1- and 2-year survival rates of 77.8 and 67 percent, respectively, compared to historical controls with median survival of 207 to 321 days. Various other immunotherapy approaches including checkpoint inhibitors, dendritic cell vaccines, and activated T-cell therapies are being investigated in canine OSA clinical trials.

Inhaled Chemotherapy

Because pulmonary metastasis is the primary cause of death in OSA, researchers have investigated delivering chemotherapy directly to the lungs via inhalation. Inhaled gemcitabine and cisplatin have both been studied in dogs with pulmonary OSA metastasis, with some evidence of response. This approach targets the site of disease most directly and may reduce systemic toxicity.

Toceranib (Palladia) and Targeted Therapy

Toceranib phosphate, the FDA-approved tyrosine kinase inhibitor (TKI) used in mast cell tumors, has shown modest activity against OSA in some studies, particularly in the metastatic setting. The identification of specific molecular targets in OSA — including VEGFR, PDGFR, and MET — continues to drive the development of more targeted therapeutic strategies.

Novel Surgical and Ablative Approaches

Advances in surgical technique continue to expand options. The 2024 Updates in Osteosarcoma review highlights emerging ablative techniques including microwave ablation and histotripsy as showing promise for local tumor control. Antibiotic-impregnated implants to reduce infection rates after limb-sparing surgery, and improved bone transport osteogenesis for limb reconstruction, continue to be refined.

Clinical Trials: If your dog has been diagnosed with OSA, asking for a referral to a veterinary teaching hospital or oncology specialist about available clinical trials is always worthwhile. Trial participation may offer access to novel treatments and contributes to advances that help future patients.

Integrative and Supportive Care

Integrative approaches can meaningfully support quality of life and may complement conventional treatment. As always, discuss all supplements and alternative therapies with your veterinary oncologist to avoid interactions with prescribed medications.

Nutrition

A high-quality, whole-food diet high in protein and omega-3 fatty acids and low in refined carbohydrates is broadly recommended in veterinary cancer nutrition. For large breed dogs with OSA, maintaining a lean body condition reduces mechanical load on affected and adjacent bones, which is particularly relevant for pain management. Fish oil supplementation (EPA and DHA) has anti-inflammatory properties and is well-tolerated alongside most chemotherapy protocols.

Physical Rehabilitation

Veterinary physical rehabilitation is an underutilized but valuable component of OSA care, particularly for post-amputation patients. Certified canine rehabilitation therapists can design programs that support recovery from surgery, optimize three-legged gait mechanics, preserve muscle mass in remaining limbs, and reduce the risk of secondary orthopedic complications. Hydrotherapy (underwater treadmill) is especially well-suited to post-amputation rehabilitation.

Nutraceuticals

• Omega-3 fatty acids (EPA/DHA from fish oil) — well-supported anti-inflammatory; may modestly reduce pain and support immune function
• Turmeric/curcumin — anti-inflammatory; some in vitro evidence for anti-tumor activity; use with caution if on chemotherapy
• Yunnan Baiyao — used for its hemostatic and anti-inflammatory properties; sometimes used when bone tumors are at risk for bleeding
• Medicinal mushrooms (turkey tail, reishi, maitake) — immunomodulatory; often incorporated into integrative oncology protocols
• Vitamin D — emerging evidence linking Vitamin D status to OSA outcomes; discuss supplementation with your veterinarian

Acupuncture

Veterinary acupuncture has reasonable evidence for efficacy in managing musculoskeletal pain and may provide meaningful analgesic support alongside conventional pain management. It is particularly useful for dogs managing chronic pain during palliative treatment or in the post-amputation period.

The Amputation Decision: Addressing Owner Concerns

The prospect of amputation is one of the most emotionally difficult aspects of an OSA diagnosis for many owners. It is natural to feel hesitation, grief, or even guilt about this decision. Understanding the evidence can help families approach it with greater clarity.

Do Dogs Do Well After Amputation?

The evidence on this is unambiguous: dogs adapt to three-legged life with remarkable resilience and speed. Multiple quality-of-life studies using validated assessment tools have consistently demonstrated that amputee dogs maintain excellent mobility, continue to engage in activities they enjoy, and do not show signs of chronic distress related to limb loss. Dogs do not have the same psychological relationship with body image that humans do, and they do not mourn the lost limb.

Most large breed dogs are weight-bearing on the remaining three limbs within days to a few weeks of surgery and return to activities such as walking, playing, and swimming. The concern that a heavy dog cannot manage on three legs is frequently raised but is rarely borne out in clinical practice — even giant breed dogs typically adapt well.

What About Concurrent Orthopedic Disease?

Dogs with significant arthritis or orthopedic disease in other limbs require careful assessment before amputation, as the increased load on remaining limbs can exacerbate those conditions. A thorough orthopedic examination of all four limbs should be part of the pre-amputation workup. In some cases, concurrent orthopedic conditions can be managed medically; in others, they may make amputation inadvisable and guide the decision toward limb-sparing or palliative approaches.

Owner Experience: Many owners who were initially uncertain about amputation report that it was the right decision for their dog and their family. The relief of pain that amputation provides is often dramatic and immediate — owners frequently say their dog "came back to life" within days of surgery.

Palliative and Hospice Care

For families who choose not to pursue surgery or chemotherapy — whether due to financial constraints, the dog's overall health status, advanced age, or personal values — palliative and hospice care focused entirely on quality of life is a valid, loving, and dignified path. The goal of palliative care is not to extend life at the cost of comfort, but to ensure that the time remaining is as pain-free and enjoyable as possible.

A robust palliative protocol for OSA typically includes multimodal pain management (NSAIDs, gabapentin, amantadine, bisphosphonates, and opioids as needed), palliative radiation if accessible, activity modification, nutritional support, and regular veterinary reassessment. Discussing end-of-life planning proactively — including quality-of-life benchmarks, fracture risk, and euthanasia criteria — allows families to make thoughtful decisions without the added burden of crisis.

Perspective: Choosing palliative care over aggressive treatment is not giving up. It is a compassionate choice that prioritizes quality of life and dignity. Dogs on well-managed palliative protocols can experience weeks to months of comfortable, enjoyable life.

Frequently Asked Questions

My large breed dog is limping — should I be worried about osteosarcoma?

Any persistent lameness in a large or giant breed dog — especially one that is progressive, associated with localized limb swelling, and not improving with rest — warrants prompt veterinary evaluation including radiographs of the affected limb. Osteosarcoma is not the only cause of lameness, and many cases will have a more benign explanation. However, because early diagnosis allows for more treatment options and better pain management, it is always better to investigate sooner rather than later. If your veterinarian's radiographs raise concern for OSA, ask for a referral to a board-certified veterinary surgeon or oncologist.

How much pain is my dog in?

The pain of osteosarcoma is considered among the most severe in veterinary medicine and is comparable to the bone pain experienced by human patients with bone metastases — which pain specialists consistently rate among the most difficult pain syndromes to manage. Because dogs are stoic and naturally mask pain, visible lameness often represents substantial underlying suffering. If your dog has been diagnosed with OSA and is not on aggressive pain management, please discuss this with your veterinarian urgently. No dog with OSA should go without adequate analgesia.

Can osteosarcoma be cured?

Long-term disease-free survival is achievable in a minority of dogs with OSA. The primary obstacle to cure is micrometastatic disease that is present but undetectable at the time of diagnosis and that progresses despite chemotherapy. Research into more effective systemic therapies — particularly immunotherapy — is ongoing and represents the most promising avenue for improving cure rates. The ADXS-HER2 immunotherapy pilot study showed 1- and 2-year survival rates of 77.8 and 67 percent in a small cohort — dramatically higher than historical controls. For the majority of dogs, the realistic goal of treatment is to extend good-quality life for as long as possible.

Is amputation the only option?

No — amputation is the most commonly recommended surgical approach for appendicular OSA, but alternatives exist. Limb-sparing surgery is available for appropriately selected cases, most effectively for distal radial tumors. Stereotactic body radiation therapy is now a routine option at specialized centers for local tumor control. Palliative radiation provides effective pain relief without surgery. The right approach depends on tumor location, patient health, owner preferences, and access to specialized facilities. A veterinary oncologist and surgeon working together can outline the full range of options available for your specific dog.

My dog is 10 years old. Is treatment worth it at this age?

Age alone should not determine whether treatment is pursued. Dogs of 10, 12, or even older can tolerate amputation and chemotherapy well, provided they are in otherwise good health. Chronological age is less important than physiological health — an assessment of cardiac and renal function, body condition, and overall vitality is far more meaningful than the number on the birth certificate. Many owners of older dogs who pursue treatment report that their dog handled it well and that the additional time gained was deeply valuable. Discuss your dog's individual health status with your veterinarian and oncologist.

What is pathologic fracture and how do I recognize it?

A pathologic fracture occurs when the bone weakened by the OSA tumor breaks, either spontaneously or with minimal trauma. It is a serious and often irreversible complication that typically ends the possibility of surgical limb salvage and marks a critical decision point in the dog's care. Signs include sudden, dramatic worsening of lameness, the dog becoming completely non-weight-bearing, obvious limb deformity, and extreme pain. A pathologic fracture is a veterinary emergency. If you suspect this has occurred, seek emergency care immediately and be prepared for a conversation about euthanasia, as fractures in tumor-bearing bone do not heal.

How do bisphosphonates help with bone cancer pain?

Bisphosphonates (pamidronate and zoledronate are most commonly used in dogs) work by inhibiting osteoclasts — the cells that break down bone. In osteosarcoma, abnormal osteoclast activity contributes to bone destruction and pain. By suppressing this activity, bisphosphonates reduce bone resorption, slow the structural weakening of affected bone, and have direct analgesic effects through mechanisms that are still being characterized. They are given as intravenous infusions, typically monthly. Studies in dogs have demonstrated significant pain reduction, and they are considered an important component of comprehensive OSA pain management.

What does metastasis look like, and when does it typically occur?

Pulmonary (lung) metastasis is by far the most common form of distant spread in canine OSA, occurring in the vast majority of patients — more than 90 percent ultimately develop it. On chest radiographs or CT, metastatic nodules appear as rounded soft-tissue densities within the lung fields. Early metastatic nodules may be too small to detect on imaging — this is what is meant by "micrometastatic disease," which is estimated to be present in 90 to 95 percent of dogs at the time of diagnosis. Clinically detectable pulmonary metastasis typically develops within 4 to 6 months in dogs treated with surgery alone, and later in dogs receiving adjuvant chemotherapy. Signs of pulmonary metastasis include coughing, exercise intolerance, labored breathing, and reduced stamina.

Are there clinical trials available for OSA?

Yes, and osteosarcoma is one of the most actively studied cancers in veterinary oncology, in part because of its importance as a comparative oncology model. Trials investigating immunotherapy approaches, novel chemotherapy combinations, inhaled drug delivery, targeted molecular therapies, and new surgical techniques are regularly conducted at veterinary teaching hospitals. Participation in a clinical trial may offer access to cutting-edge treatments, often at reduced cost, while directly contributing to advances that benefit both dogs and human patients with bone cancer. Ask your veterinary oncologist for current trial options, or search the Veterinary Cancer Society clinical trial database.

When is it time to consider euthanasia?

This is the most painful question families face, and there is no single right answer. Quality-of-life assessment tools — such as the HHHHHMM Scale developed by Dr. Alice Villalobos — can provide a structured framework for evaluating pain, appetite, hydration, hygiene, happiness, mobility, and overall quality of life. In general, when a dog's pain cannot be adequately controlled, when they have lost interest in food and activities they once enjoyed, when mobility has deteriorated to a point that eliminates quality of life, or when pathologic fracture has occurred, it is appropriate to have an honest conversation with your veterinarian about humane euthanasia. Choosing a peaceful death at the right moment — before suffering becomes unmanageable — is one of the most profound acts of love available to us as pet owners.

References

1. Bryan JN. Updates in Osteosarcoma. Veterinary Clinics of North America: Small Animal Practice, 54(3):523–539, 2024. https://pubmed.ncbi.nlm.nih.gov/38158305/

2. Tuohy JL, Shaevitz MH, Garrett LD, Ruple A, Selmic LE. Demographic characteristics, site and phylogenetic distribution of dogs with appendicular osteosarcoma: 744 dogs (2000–2015). PLOS ONE, 2019. https://pmc.ncbi.nlm.nih.gov/articles/PMC6936818/

3. Makielski KM, Mills LJ, Sarver AL, et al. Risk factors for development of canine and human osteosarcoma: a comparative review. Veterinary Sciences, 6(2):48, 2019. https://www.mdpi.com/2306-7381/6/2/48

4. Kirpensteijn J, Zon MEVA, Endenburg N. Prognostic factors in canine appendicular osteosarcoma — a meta-analysis. BMC Veterinary Research, 8:56, 2012. https://pmc.ncbi.nlm.nih.gov/articles/PMC3482154/

5. Simpson S, Dunning MD, de Brot S, Grau-Roma L, Mongan NP, Rutland CS. Comparative review of human and canine osteosarcoma: morphology, epidemiology, prognosis, treatment and genetics. Acta Veterinaria Scandinavica, 59(1):71, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5655853/

6. Morello E, Martano M, Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: similarities and differences with human osteosarcoma. Veterinary Journal, 189(3):268–277, 2011. https://www.sciencedirect.com/science/article/abs/pii/S1090023310002881

7. Szewczyk M, Lechowski R, Zabielska K. What do we know about canine osteosarcoma treatment? Review. Veterinary Research Communications, 39(1):61–67, 2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4330401/

8. Luu AK, Wood GA, Viloria-Petit AM. Recent advances in the discovery of biomarkers for canine osteosarcoma. Frontiers in Veterinary Science, 8:734965, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8517113/

9. Fenger JM, London CA, Kisseberth WC. Canine osteosarcoma: a naturally occurring disease to inform pediatric oncology. ILAR Journal, 55(1):69–85, 2014. https://pubmed.ncbi.nlm.nih.gov/24936032/

10. Simpson S, Rizvanov AA, Jeyapalan JN, et al. Canine osteosarcoma in comparative oncology: molecular mechanisms through to treatment discovery. Frontiers in Veterinary Science, 9:965391, 2022. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2022.965391/full

11. Neihaus SA, Locke JE, Barger AM, Borst LB, Goring RL. A novel method of core aspirate cytology compared to fine-needle aspiration for diagnosing canine osteosarcoma. Journal of the American Animal Hospital Association, 47(5):317–323, 2011. https://pubmed.ncbi.nlm.nih.gov/21852507/

12. Sabattini S, Renzi A, Buracco P, et al. Comparative assessment of the accuracy of cytological and histologic biopsies in the diagnosis of canine bone lesions. Journal of Veterinary Internal Medicine, 31(3):864–871, 2017. https://pmc.ncbi.nlm.nih.gov/articles/PMC5435042/

13. Oikonomidis IL, Tsouloufi TK. Diagnostic accuracy of cytology for canine osteosarcoma compared to histopathology. Veterinary Evidence, 6(2), 2021. https://veterinaryevidence.org/index.php/ve/article/view/399

14. Mason NJ. A promising potential treatment for osteosarcoma. DVM360, 2023. https://www.dvm360.com/view/a-promising-potential-treatment-for-osteosarcoma

15. Momen M, Kohler NL, Binversie EE, Dentino M, Sample SJ. Heritability and genetic variance estimation of osteosarcoma in Irish Wolfhound, using deep pedigree information. Companion Animal Health and Genetics, 8(1):9, 2021. https://pmc.ncbi.nlm.nih.gov/articles/PMC8502365/

16. Frontiers in Veterinary Science — Editorial Board. Osteosarcoma of the appendicular skeleton in dogs: consensus and guidelines. Frontiers in Veterinary Science, 2025. https://www.frontiersin.org/journals/veterinary-science/articles/10.3389/fvets.2025.1633593/full

17. Martin TW, Griffin L, Custis J, et al. Outcome and prognosis for canine appendicular osteosarcoma treated with stereotactic body radiation therapy in 123 dogs. Veterinary and Comparative Oncology, 19(2):284–294, 2021. https://pubmed.ncbi.nlm.nih.gov/33403752/

18. Altwal J, et al. Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy. Veterinary and Comparative Oncology, 2024. https://onlinelibrary.wiley.com/doi/abs/10.1111/vco.12960

19. Washington State University Veterinary Teaching Hospital. Canine osteosarcoma. WSU Veterinary Teaching Hospital, 2021. https://hospital.vetmed.wsu.edu/2021/05/25/canine-osteosarcoma/

20. Cornell Richard P. Riney Canine Health Center. Osteosarcoma in dogs. Cornell University College of Veterinary Medicine, 2024. https://www.vet.cornell.edu/departments-centers-and-institutes/riney-canine-health-center/canine-health-topics/osteosarcoma-dogs

---

This article is intended for educational purposes only and does not constitute veterinary medical advice. Always consult a licensed veterinarian or board-certified veterinary oncologist for guidance specific to your dog's health needs.